bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-31-1763

Order Name:
Pancreatic Elastase, Stool **

 
Useful For:
Diagnosis of exocrine pancreatic insufficiency in case of unexplained diarrhea, constipation, steatorrhea, flatulence, weight loss, upper abdominal pain, and food intolerances.

Monitoring of exocrine pancreatic function in cystic fibrosis, diabetes mellitus, or chronic pancreatitis.
 
Methodology:
Enzyme-Linked Immunosorbent Assay (ELISA)
 
AliasesName:
Test ID: ELASF    
Pancreatic Elastase, Feces
 
 
 
Test Code:
090-31-1763

Order Name:
Pancreatic Elastase, Stool **

 
Collection Specimen Or Container:
Fresh random stool 5 grams.
นำส่งห้องปฏิบัติการทันที, ไม่แนะนำให้ส่งตรวจอุจจาระที่เป็นน้ำ และไม่รับตรวจอุจจาระที่เก็บจากผ้าอ้อม

Collection Instructions:
1. Collect a fresh random fecal specimen, no preservatives.
2. If specimen is sent refrigerate, send immediately after collection.
3. If specimen cannot be sent immediately, freeze and send frozen.
Additional Information:  
Testing cannot be added on to a previously collected specimen.
 
Specimen Testing Type:
Feces (Stool), minimum volume 2 g.
 
Sub Mission Container:
Stool Container
 
Rejection Criteria:
Specimens collected from diapers = Reject
Refrigerated or ambient specimens received more than 72 hours post collection will be rejected.
 
 
Specimen Stabillity:
Specimen Type  Temperature   Time
Feces (stool) Frozen (preferred) 28 days
Feces (stool) Ambient  72 hours
Feces (stool) Refrigerated 72 hours
 
 
 
Test Code:
090-31-1763

Order Name:
Pancreatic Elastase, Stool **

 
Method detail:
Enzyme-Linked Immunosorbent Assay (ELISA)
 
Schedule:
N/A **Sent out to MAYO, USA
 
Turnaround Time:
Received specimen to report within 2-3 weeks 
 
Performing Location:
MAYO Laboratory
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-31-1763

Order Name:
Pancreatic Elastase, Stool **

 
 
Clinical Information:

Pancreatic elastase (PE) is a proteolytic enzyme produced in the pancreatic acinar cells. It is released as a zymogen, which is then converted to an active enzyme in the duodenum by trypsin. PE has an important role in digestion, and proteolytically degrades proteins preferentially at alanine residues.

Exocrine pancreatic insufficiency (EPI) is described as a reduction in pancreatic enzyme activity below the normal digestive threshold level. Clinical symptoms of EPI include steatorrhea, bloating, abdominal discomfort, and weight loss. EPI is most commonly caused by chronic pancreatitis but can also be associated with pancreatic cancer, pancreatic surgery, necrotizing acute pancreatitis, cystic fibrosis, inflammatory bowel disease (both Crohn’s disease and ulcerative colitis), diabetes (types I and II), gastric surgery, short bowel syndrome, and Zollinger-Ellison syndrome. If left untreated, patients with EPI can experience weight loss and significant nutrient deficiencies. Treatment for EPI centers on administration of pancreatic enzyme replacement therapy.

Stool testing is a critical component for the diagnosis of EPI. The 72-hour fecal fat test is useful for evaluating for the presence of steatorrhea. However, this testing is cumbersome for the patient and not easily tolerated due to the requirement of consuming 100 g fat/day. An alternate to the 72-hour fecal fat test is the measurement of PE in stool. The amount of PE in stool is representative of pancreatic enzyme production; patients with EPI may have reduced concentrations of PE in feces.

 
Reference Value:
<100 mcg/g (Severe Pancreatic Insufficiency)
100-200 mcg/g (Moderate Pancreatic Insufficiency)
>200 mcg/g (Normal)
Reference values apply to all ages.
 
Interpretation:

Pancreatic elastase concentrations above 200 mcg/g are normal and are not indicative of exocrine pancreatic insufficiency.

Pancreatic elastase concentrations from 100-200 mcg/g are suggestive for moderate exocrine pancreatic insufficiency.

Pancreatic elastase concentrations below 100 mcg/g are consistent with exocrine pancreatic insufficiency.

 
Clinical Reference:
www.mayocliniclabs.com (Retrieved: 30 Nov 2021)